Business Context and Reporting Period
This Form 8-K is filed by Qualigen Therapeutics, Inc. (not Aixcrypto Holdings, Inc., as noted in the metadata request) on July 11, 2024. The filing reports a change in the company's certifying accountant. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol QLGN.
Key Financial Metrics
This filing does not contain specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the administrative change of the independent registered public accounting firm.
Material Changes
- Dismissal of Former Auditor: On July 11, 2024, the company dismissed Baker Tilly US, LLP, which had served as the independent auditor since 2018.
- Engagement of New Auditor: On the same date, the company engaged WithumSmith+Brown, PC (Withum) as the new independent registered public accounting firm to audit the financial statements for the year ending December 31, 2024.
- Audit Committee Approval: Both the dismissal and the new engagement were approved by the company's Audit Committee.
Guidance, Risks, and Contingencies
- Going Concern Issues: The reports issued by the former auditor (Baker Tilly) for fiscal years 2022 and 2023 included an explanatory paragraph describing conditions that raised substantial doubt about the Company's ability to continue as a going concern.
- Material Weakness: The former auditor communicated a material weakness to the Audit Committee. The company has authorized the former auditor to discuss this weakness with the successor firm.
- No Disagreements: The company reported no disagreements with the former auditor regarding accounting principles, practices, or financial statement disclosures during the engagement period.
- No Prior Consultation: The company did not consult with the new auditor (Withum) on any accounting or auditing matters prior to the engagement.
Investor Verification Checklist
- Verify the specific nature of the material weakness communicated by Baker Tilly, as this impacts internal controls over financial reporting.
- Review the company's most recent 10-K or 10-Q filings to assess the current status of the going concern conditions noted in prior audit opinions.
- Confirm the timeline for the transition of audit responsibilities between Baker Tilly and Withum.
- Examine Exhibit 99.1 (Letter from Baker Tilly) to ensure the former auditor agrees with the company's statements regarding the dismissal.